HDAC6 inhibitors demonstrated efficacy in HSPB1‐associated CMT2F transgenic mouse models, correcting axonal transport defects and reversing the CMT phenotype caused by HSPB1 mutations.69, 70, 71, 72. This evidence concerns the gene HSPB1 and Charcot-Marie-Tooth disease.